I’ve seen companies stay flat even on approval by the FDA and then go on to have hugely successful drugs and a massive market cap. As I said, it’s the long-term that matters, not the “trading”, manipulated or not.
It also takes a while for big news to get circulated and digested. It depends on the circumstances, but frequently, a journal article is not fully understood, in terms of implications just from publication. It needs to be digested and explained to the larger marketplace.
Journal articles also barely touch on the sponsor, that is about PR and major publications will frequently discuss the research and article without ever mentioning the company except in passing, maybe, deep in the article. Plus it’s OTC.
Those here just for the momentary pops, typically are not longs. I don’t care if they are made happy, because they don’t really care about the endeavor.
Market Data 
Markets 
AI
